StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report sent to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright lowered their price target on shares of Trevena from $225.00 to $125.00 and set a buy rating on the stock in a report on Thursday, May 16th.
Get Our Latest Research Report on Trevena
Trevena Stock Down 1.8 %
Trevena (NASDAQ:TRVN – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($9.25) by $9.02. The firm had revenue of $0.33 million for the quarter. Equities research analysts expect that Trevena will post -32.25 EPS for the current year.
Institutional Investors Weigh In On Trevena
An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent reporting period. 13.56% of the stock is owned by institutional investors and hedge funds.
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Featured Articles
- Five stocks we like better than Trevena
- Learn Technical Analysis Skills to Master the Stock Market
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.